PAXLOVID.txt 3/24/2023 The evaluation of protease inhibition for COVID-19 in high-risk patients (EPIC-HR) trial findings indicated that orally administered nirmatrelvir-ritonavir (Paxlovid) lowered COVID-19-associated hospitalization risks by 89% March 21, 2023 - CHECK FOR SIDE EFFECTS. I've read that it might not be good for CKD patients: Paxlovid isn't recommended for people with severe kidney or liver problems. If you have moderate kidney problems, you'll only take one nirmatrelvir tablet per dose instead of two Paxlovid isn't recommended for people with severe kidney or liver problems. If you have moderate kidney problems, you'll only take one nirmatrelvir tablet per dose instead of two https://www.goodrx.com/paxlovid/dosage-guide CHECK WITH YOUR DOCTOR BEFORE TAKING PAXLOVID https://www.news-medical.net/news/20230321/Paxlovid-is-8025-effective-when-taken-within-5-days-of-severe-COVID.aspx Everything You Need to Know About Paxlovid Paxlovid reduces serious risks from Omicron variants The coronavirus will likely evade Paxlovid eventually Coronavirus Resource Center - Harvard Paxlovid = Reduced risk for 10 of 12 long-COVID conditions Paxlovid May Reduce Long Covid Risk, but Access Is About to Get Worse You probably know of Paxlovid as an antiviral drug that can help make COVID infections less severe. Now, a new study found that Paxlovid reduces the risk of long COVID as well. They compared outcomes in people who received Paxlovid within 5 days of COVID symptoms with people who did not receive Paxlovid. Remember - NOT considered good for Kidney patients - check for other caveats I am NOT a doctor. I have had NO medical training of any kind. I am NOT responsible for what you do, or do not do. http://www.woodsmall.com/